Maintenance Therapy in Small Cell Lung Cancer

In this episode of OncoPharm, host Jon Bazar discusses maintenance therapy for small cell lung cancer, focusing on the MFORTE study and the recent approval of lurbinectadine maintenance in combination with atezolizumab. He compares MFORTE to the Empower 133 and Caspian studies, detailing patient screening, enrollment, and randomization. Bazar highlights key data points, including median overall survival rates and the significance of prophylactic GCSF and anti-emetic use. He also explores the Delphi303 study, which investigates tarlatamab in combination with atezolizumab or durvalumab, noting promising early results regarding overall survival. The episode concludes with a mention of ongoing trials and potential future treatments, emphasizing the evolving landscape of maintenance therapy for small cell lung cancer.